BMB 101
Alternative Names: BMB-101Latest Information Update: 23 Oct 2024
Price :
$50 *
At a glance
- Originator Bright Minds Biosciences; Firefly Neuroscience
- Developer Bright Minds Biosciences
- Class Antiepileptic drugs; Behavioural disorder therapies; Drug withdrawal therapies
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Absence epilepsy; Pitt-Hopkins syndrome
- Phase I Dravet syndrome
- Preclinical Binge-eating disorder; Lennox-Gastaut syndrome; Opioid-related disorders
Most Recent Events
- 21 Oct 2024 Firefly Neuroscience and Bright Minds Biosciences collaborates for the development of BMB 101 for Pitt-Hopkins syndrome
- 16 Oct 2024 Firefly Neuroscience and Bright Minds Biosciences collaborates for the development of BMB 101 for Dravet syndrome
- 12 Sep 2024 Phase-II clinical trials in Absence epilepsy (Treatment-resistant) in Australia (PO) (NCT06401538)